ADI News en ADI offers advice and support during COVID-19 <!--break--> <p><strong>17 March 2020</strong> &ndash; During these unprecedented times, ADI is bringing together news, resources, stories, advice and support for anyone affected by dementia around the world. This web page will be dedicated to resources relating to the 2019 coronavirus disease (COVID-19) pandemic and will be updated on a regular basis.</p> <p>Older people, especially living with dementia, may become more anxious, angry, stressed, agitated, and withdrawn during the outbreak and it is easy to become overwhelmed with the scale and frequency of news updates. For those in quarantine these difficulties may be further exacerbated. Whether you are a person living with dementia, a carer, a healthcare professional, or otherwise, we want to provide you with information that could help alleviate some of these challenges. We all need to provide and exchange practical and emotional support during this difficult time and ADI&rsquo;s aim is for this page to provide examples for inspiration, shared experience and guidance.</p> <p>We strongly suggest that you start by watching this video from Professor Huali Wang, Executive Vice President of ADI&rsquo;s member association in China, Alzheimer&rsquo;s Disease Chinese (ADC), which explains how China has addressed the specific challenges of people living with dementia during the outbreak, and how this advice can be used I other countries across the world.</p> <h3><a href="">Watch the video here.</a></h3> <p>Also available with&nbsp;<a href="">Spanish</a> and <a href="">French</a> subtitles.</p> <p>Below are some useful resources. In the interests of solidarity and information sharing, please email <a href=""></a> if you have any further resources to add.</p> <hr /> <h3><strong>Some useful resources:</strong></h3> <ul> <li><a href="">The Lancet article &#39;Dementia care during COVID-19&#39; by Huali Wang, Paola Barbarino et al </a></li> <li><a href="">Up-to-date advice on COVID-19 from the WHO</a></li> <li><a href="">WHO Whatsapp alerts</a></li> <li><a href="">COVID Symptom Tracker</a></li> <li><a href="">WHO Information Note note on COVID-19 and noncommunicable diseases</a></li> <li><a href="">WHO guidance on Infection prevention and control guidance for long-term care facilities in the context of COVID-19</a></li> <li><a href=",-prevention-and-control-of-covid-19-in-prisons-and-other-places-of-detention-2020">WHO&#39;s guidance on Preparedness, prevention and control of COVID-19 in prisons and other places of detention (2020)</a></li> </ul> <p><img alt="" src="/sites/default/files/img/22_iStock-532117456.jpg" style="width: 300px; height: 200px; margin-left: 20px; margin-right: 20px;" /><img alt="" src="/sites/default/files/img/5_iStock-956845104.jpg" style="width: 300px; height: 200px;" /></p> <p><strong>Blogs</strong></p> <ul> <li>Canada -&nbsp;<a href="">Alzheimer Society of Canada: Tips for people with dementia, caregivers and families</a></li> <li>France -&nbsp;<a href="">France Alzheimer&#39;s blog on confinement with a family member with Alzheimer&#39;s: activities to do at home (French)</a></li> <li>Italy - <a href="">Mario Possenti:&nbsp;Italy in crisis: ADI member Alzheimer Italia on the impact of COVID-19 on people with dementia and how they have adapted to support them</a></li> <li>Malaysia -&nbsp;<a href="">Datin Jacqueline&nbsp;Wong:<b>&nbsp;</b>Community initiatives from Malaysia to help the elderly and vulnerable during the COVID-19 outbreak</a></li> <li>Spain -&nbsp;<a href="">Jes&uacute;s Rodrigo:&nbsp;ADI&rsquo;s member CEAFA reveals how they have adapted to support people living with dementia during COVID-19</a></li> <li>USA -&nbsp;<a href="">Dr. Francis Collins, the Director of the NIH on the importance of social distancing</a>​​​​​​​</li> </ul> <p><strong>Mental health and wellbeing</strong></p> <ul> <li><a href="">The WHO&#39;s mental health advice during COVID-19</a></li> <li><a href="">The WHO&#39;s guide to coping with stress during COVID-19</a>&nbsp;(Also in&nbsp;<a href="">Arabic</a>, <a href="">Chinese</a>, <a href="">French</a>, <a href="">Russian</a> and <a href="">Spanish</a>)</li> <li>UK -&nbsp;<a href="">Dementia UK&#39;s calming techniques for people living with dementia</a></li> <li>UK -&nbsp;<a href="">The Independent&#39;s advice on how to manage your mental health during self-isolation</a></li> <li>Canada -&nbsp;<a href="">Ontario Neurodegenerative Disease Research Initiative&#39;s guidance on social distancing</a></li> <li><a href="">QuaranTrain - an International platform providing daily online support and information on exercise and everyday activities during COVID-19</a></li> <li><a href="">The Inter Agency Standing Committee&nbsp;(IASC)&#39;s Interim Briefing Note Addressing Mental Health and Psychosocial Aspects of COVID-19 Outbreak</a></li> </ul> <p><strong>ADI member resources for carers and people with dementia</strong></p> <ul> </ul> <ul> <li>USA -&nbsp;<a href="">Alzheimer&#39;s Association&#39;s advice for family carers</a></li> <li>USA - <a href="">Alzheimer&#39;s Association&#39;s&nbsp;Tips for Dementia Caregivers in Long-Term or Community-Based Settings</a></li> <li>New Zealand -&nbsp;<a href="">Alzheimers New Zealand&#39;s advice for people with dementia</a></li> <li>New Zealand -&nbsp;<a href="">Alzheimers New Zealand&#39;s advice on supporting people with dementia</a></li> <li>UK -&nbsp;<a href=";utm_medium=email&amp;utm_campaign=GenNewsletter&amp;utm_content=26032020&amp;dm_i=57EL,6JDB,2DU7RA,ON4Y,1">Alzheimer&#39;s Society&#39;s information on COVID-19 for people with dementia</a></li> <li>Bosnia Herzegovina -&nbsp;<a href="/sites/default/files/pdfs/Dementia-at-the-time-of-Covid-19-Alzheimer-udruz%CC%8Cenje-AiR.pdf">Alzheimer udruženje AiR&#39;s guidance on dementia at the time of COVID-19</a></li> <li>Australia -&nbsp;<a href="">Dementia Australia&#39;s Dementia Help Sheets to navigate coronavirus COVID-19</a></li> <li>France -&nbsp;<a href="">France Alzheimer&#39;s advice for people with dementia and carers</a></li> <li>Slovenia -&nbsp;<a href="/sites/default/files/pdfs/Spominc%CC%8Cica-10-Tips-English.pdf">Spominčica - Alzheimer Slovenija&#39;s 10 tips for those having a person with dementia at home</a></li> <li>Indonesia/Netherlands -&nbsp;<a href="">Stichting Alzheimer Indonesia Nederland&rsquo;s advice on COVID-19</a></li> <li><a href="/sites/default/files/pdfs/TADA%27s-Reference-Handbook-of-Dementia-Care-COVID-19%20.pdf">TADA&#39;s Reference Handbook of Dementia Care responding to COVID-19</a></li> <li><a href="/sites/default/files/pdfs/MHPSS-Key%20messages-EN-min.pdf">Key messages&nbsp;on China&#39;s Mental Health and Psychological Support for Older Adults during the Outbreak of COVID-19 (English)</a></li> <li><a href="/sites/default/files/pdfs/MHPSS-Key%20messages-CN.pdf">Key messages&nbsp;on China&#39;s Mental Health and Psychological Support for Older Adults during the Outbreak of COVID-19 (Chinese)</a></li> </ul> <p><strong>Other resources for carers and people with dementia</strong></p> <ul> <li>UK -&nbsp;<a href="">A UK-based carer support group on Facebook</a></li> <li>Ireland -&nbsp;<a href="">Care Alliance Ireland&rsquo;s advice for family carers</a></li> <li>UK -&nbsp;<a href="">Dementia UK&#39;s information for families looking after&nbsp;people with dementia</a></li> <li>UK -&nbsp;<a href=";extid=sWMre82aUiFGLQOL">Dr Jennifer Bute&#39;s&nbsp;advice on dementia and COVID-19</a></li> <li>USA -&nbsp;<a href=";utm_source=Global+Health+NOW+Main+List&amp;utm_campaign=6efbbd288a-EMAIL_CAMPAIGN_2020_03_26_12_33&amp;utm_medium=email&amp;utm_term=0_8d0d062dbd-6efbbd288a-2992725">New York Times article &#39;When Dementia Meets the Coronavirus Crisis&#39;&nbsp;</a></li> <li>Sweden -&nbsp;<a href="">Swedish Care International&#39;s Q&amp;A series to support caregivers and people with dementia&nbsp;</a></li> <li><a href="">Resources to support community and institutional Long-Term Care responses to COVID-19</a></li> </ul> <p><strong>In Spanish</strong></p> <ul> <li>Dominican Republic -&nbsp;<a href="">Recomendaciones COVID-19 &ndash; Dra Daisy Acosta, Republica Dominicana</a></li> </ul> <p><strong>In Portuguese</strong></p> <ul> <li>Brazil -&nbsp;<a href="">Sociedade Brasileira de Geriatria e Gerontologia - Recomenda&ccedil;&otilde;es para Preven&ccedil;&atilde;o e Controle de infec&ccedil;&otilde;es por coronav&iacute;rus (SARS-Cov-2) em Institui&ccedil;&otilde;es de Longa Perman&ecirc;ncia para Idosos (ILPIs)</a></li> <li>Brazil -&nbsp;<a href="">Sociedade Brasileira de Geriatria e Gerontologia - Recomenda&ccedil;&otilde;es para Preven&ccedil;&atilde;o e Controle de infec&ccedil;&otilde;es por coronav&iacute;rus (SARS-Cov-2) em Institui&ccedil;&otilde;es de Longa Perman&ecirc;ncia para Idosos (ILPIs)</a></li> </ul> <p><strong>Support for Alzheimer&#39;s organisations</strong></p> <ul> <li>New Zealand -&nbsp;<a href="">Alzheimers New Zealand&#39;s guidance for local Alzheimer&#39;s organisations</a></li> </ul> <p><strong>Advice for people with NCDs and healthcare providers</strong></p> <ul> <li><a href="">NCD Alliance&#39;s response to COVID-19</a></li> <li><a href="">Links Community&rsquo;s&nbsp;guidance for health care providers and chronic disease patients</a>&nbsp;(available in multiple languages)</li> </ul> <p><strong>Older persons</strong></p> <ul> <li><a href="">A website on COVID-19 and older people in developing countries</a></li> <li><a href="">Age International&#39;s statement on the increased risk to older people in the poorest countries</a></li> <li>Canada -&nbsp;<a href="">ESOGER1, a&nbsp;socio-geriatric identification tool for seniors during COVID-19 developed by&nbsp;McGill RUISSS Centre of Excellence on Longevity</a></li> <li><a href="">Guidance from HelpAge International</a></li> <li><a href="">The Lancet: COVID-19 and the consequences of isolating in the elderly</a></li> <li><a href=";LangID=E">&ldquo;Unacceptable&rdquo; &ndash; UN expert urges better protection of older persons facing the highest risk of the COVID-19 pandemic</a></li> </ul> <p><strong>Measuring COVID-19</strong></p> <ul> <li>UK -&nbsp;<a href="">British Medical Journal&#39;s article on a Potential Impact of COVID-19 on Human Mortality (PICHM) Tool&nbsp;</a></li> </ul> <p><b>Podcasts</b></p> <ul> <li>UK -&nbsp;<a href="">Dr. Rangan Chatterjee: How to manage anxiety in the face of a global pandemic with Dr. Judson Brewer</a></li> </ul> <p><strong>A book by Huali Wang (in Chinese) on&nbsp;Psychological Support for Older Adults during the COVID-19 Outbreak</strong></p> <ul> <li><a href="">Introduction to the book</a></li> <li><a href=";openCourseId=8eecdba7a7c049309284f5bf40f10f18">Printed version of full-text book (Free online)</a></li> <li><a href=";openCourseId=0d4f3db57ae84665baf63fa60dd90bb9">Audible book (Free online)</a></li> </ul> <p><strong>Other resources</strong></p> <ul> <li><a href=";IR=T">A letter from one of Belgium&#39;s top virologists to his children with exact steps on how to keep their families safe during a pandemic</a></li> <li><a href="">AlzForum:&nbsp;Coronavirus Takes Its Toll on Alzheimer&rsquo;s Clinical Studies</a></li> <li><a href="/sites/default/files/pdfs/COVID-19%20%D0%9F%D0%BE%D0%BC%D0%BE%D1%89%D1%8C%20%D0%B1%D0%BE%D0%BB%D1%8C%D0%BD%D1%8B%D0%BC%20%D0%B4%D0%B5%D0%BC%D0%B5%D0%BD%D1%86%D0%B8%D0%B5%D0%B8%CC%86%20%281%29.pdf">Professor Huali Wang&#39;s presentation in Russian</a></li> </ul> <p><strong>ADI can only carry out our work we do with kind contributions and donations. Your support at this time would be most appreciated.&nbsp;You can donate <a href="">here</a>.&nbsp;&nbsp;</strong></p> <div class="field field-type-filefield field-field-news-fp-image"> <div class="field-label">Front Page Image:&nbsp;</div> <div class="field-items"> <div class="field-item odd"> <img class="imagefield imagefield-field_news_fp_image" width="634" height="322" alt="" src="" /> </div> </div> </div> Tue, 17 Mar 2020 12:34:14 +0000 Annie.Bliss 3726 at COVID-19: Sharing experience and advice from ADI's member association in China <!--break--> <p><strong>16&nbsp;March 2020 </strong>&ndash;&nbsp;With the COVID-19 pandemic continuing to affect more people and more countries each day, it is vital that work and support continues for people living with dementia and their carers. As result, ADI brings to you a timely and important video presentation on the continuity of care for people living with dementia during the COVID-19 outbreak.&nbsp;</p> <p>ADI is extremely grateful to Professor Huali Wang, Executive Vice President of ADI&rsquo;s member association in China, Alzheimer&rsquo;s Disease Chinese (ADC), for recording this short presentation which has global relevance. Over the last few month, Professor Wang and colleagues have experienced first-hand the challenges and responses to dementia care during the spread of the novel coronavirus.<br /> <br /> Paola Barbarino, Chief Executive of ADI, is calling on the solidarity of the community that supports and is focussed on dementia at this time.&nbsp;See Paola&rsquo;s introduction to Professor Wang&rsquo;s presentation <a href="">here</a>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br /> <br /> In this 30 minute presentation, Professor Wang explains how China has addressed the specific challenges of people living with dementia during unprecedented circumstances. Details, perspective and advice based on local experience are offered in the hope that it may help Alzheimer&rsquo;s and dementia associations globally, as well as health and care professionals, people affected by dementia and their carers.</p> <p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="" width="560"></iframe></p> <p>Professor Huali Wang&rsquo;s contact details are available at the end of the presentation for those that may have further questions.&nbsp;<br /> <br /> You can find<a href="/associations">&nbsp;here</a> the list of ADI members, Alzheimer and dementia associations around the world, as well as their contact information.</p> <h4>Some useful resources:</h4> <ul> <li><a href="">Up-to-date advice on COVID-19 from the WHO</a></li> <li><a href="">The WHO&#39;s mental health advice</a><a href="">&nbsp;during COVID-19</a></li> </ul> Mon, 16 Mar 2020 14:41:45 +0000 Taylor.Paatalo 3725 at Global Perspective Newsletter for February 2020 <p><a href="/sites/default/files/pdfs/Global-perspective-February-2020.pdf"><img alt="" src="/sites/default/files/pdfs/GP%20Feb%20Cover.PNG" style="border-width: 1px; border-style: solid; float: right; width: 91px; height: 128px;" /></a><strong>27&nbsp;February&nbsp;2020</strong>&nbsp;&ndash;&nbsp;The February 2020 edition of our Global Perspective Newsletter is now available.&nbsp;Read the latest&nbsp;news from ADI, our partners and member associations, including updates on the upcoming World Alzheimer&#39;s Month, World Alzheimer Report, and much more.&nbsp;<a href="/sites/default/files/pdfs/Global-perspective-February-2020.pdf">[read more]</a>&nbsp;</p> Mon, 02 Mar 2020 11:59:33 +0000 Taylor.Paatalo 3724 at Roche to end DIAN-TU-001 study for rare Autosomnal dominant Alzheimer's disease <!--break--> <p><strong>10 February 2020</strong>&nbsp;&ndash;<strong>&nbsp;</strong>Roche&zwnj; &zwnj;announced&zwnj; &zwnj;today&zwnj; &zwnj;that&zwnj; &zwnj;it&zwnj; &zwnj;has&zwnj; &zwnj;ended&zwnj; &zwnj;the&zwnj; &zwnj;gantenerumab&zwnj; &zwnj;arm&zwnj; &zwnj;of&zwnj; &zwnj;the&zwnj; &zwnj;Phase&zwnj;&nbsp;&zwnj;II/III&zwnj; &zwnj;DIAN-TU-001&zwnj; &zwnj;study&zwnj; &zwnj;after&zwnj; &zwnj;it&zwnj; &zwnj;failed&zwnj; &zwnj;to&zwnj; &zwnj;meets&zwnj; &zwnj;its&zwnj; &zwnj;primary&zwnj; &zwnj;endpoint&zwnj; &zwnj;in&zwnj; &zwnj;people&zwnj; &zwnj;who&zwnj; &zwnj;are&zwnj; &zwnj;affected&zwnj;&nbsp;&zwnj;by&zwnj; &zwnj;early&zwnj; &zwnj;onset&zwnj; &zwnj;Autosomal&zwnj; &zwnj;dominant&zwnj; &zwnj;Alzheimer&rsquo;s&zwnj; &zwnj;disease.&zwnj;&nbsp;&zwnj;</p> <p>Autosomal&zwnj; &zwnj;dominant&zwnj; &zwnj;AD&zwnj; &zwnj;is&zwnj; &zwnj;a&zwnj; &zwnj;rare,&zwnj; &zwnj;inherited&zwnj; &zwnj;form&zwnj; &zwnj;of&zwnj; &zwnj;Alzheimer&rsquo;s&zwnj; &zwnj;disease,&zwnj; &zwnj;which&zwnj; &zwnj;accounts&zwnj; &zwnj;for&zwnj; &zwnj;less&zwnj;&nbsp;&zwnj;than&zwnj; &zwnj;1%&zwnj; &zwnj;of&zwnj; &zwnj;all&zwnj; &zwnj;Alzheimer&rsquo;s&zwnj; &zwnj;related&zwnj; &zwnj;disease&zwnj; &zwnj;globally.&zwnj;&nbsp;&zwnj;</p> <p>Spearheaded&zwnj; &zwnj;by&zwnj; &zwnj;Washington&zwnj; &zwnj;University&zwnj; &zwnj;School&zwnj; &zwnj;of&zwnj; &zwnj;Medicine&zwnj; &zwnj;in&zwnj; &zwnj;St.&zwnj; &zwnj;Louis,&zwnj; &zwnj;US,&zwnj; &zwnj;the&zwnj; &zwnj;DIAN-TU-001&zwnj;&nbsp;&zwnj;is&zwnj; &zwnj;a&zwnj; &zwnj;Phase&zwnj; &zwnj;II/III&zwnj; &zwnj;study&zwnj; &zwnj;which&zwnj; &zwnj;tested&zwnj; &zwnj;two&zwnj; &zwnj;investigational&zwnj; &zwnj;therapies&zwnj; &zwnj;against&zwnj; &zwnj;placebo,&zwnj; &zwnj;to&zwnj; &zwnj;see&zwnj; &zwnj;if&zwnj; &zwnj;either&zwnj;&nbsp;&zwnj;of&zwnj; &zwnj;the&zwnj; &zwnj;two&zwnj; &zwnj;therapies&zwnj; &zwnj;could&zwnj; &zwnj;slow&zwnj; &zwnj;the&zwnj; &zwnj;rate&zwnj; &zwnj;of&zwnj; &zwnj;cognitive&zwnj; &zwnj;decline,&zwnj; &zwnj;as&zwnj; &zwnj;well&zwnj; &zwnj;as&zwnj; &zwnj;improve&zwnj; &zwnj;the&zwnj; &zwnj;biomarkers&zwnj;&nbsp;&zwnj;in&zwnj; &zwnj;people&zwnj; &zwnj;who&zwnj; &zwnj;are&zwnj; &zwnj;known&zwnj; &zwnj;to&zwnj; &zwnj;have&zwnj; &zwnj;a&zwnj; &zwnj;genetic&zwnj; &zwnj;mutation&zwnj; &zwnj;for&zwnj; &zwnj;inherited&zwnj; &zwnj;Alzheimer&rsquo;s&zwnj; &zwnj;disease.&zwnj; &zwnj;The&zwnj; &zwnj;two&zwnj;&nbsp;&zwnj;investigational&zwnj; &zwnj;therapies&zwnj; &zwnj;tested&zwnj; &zwnj;were&zwnj; &zwnj;Roche&rsquo;s&zwnj; &zwnj;gantenerumab&zwnj; &zwnj;and&zwnj; &zwnj;Eli&zwnj; &zwnj;Lilly&rsquo;s&zwnj; &zwnj;solanenezum.&zwnj;&nbsp;&zwnj;</p> <p>Gantenerumab&zwnj; &zwnj;will&zwnj; &zwnj;continue&zwnj; &zwnj;to&zwnj; &zwnj;be&zwnj; &zwnj;studied&zwnj; &zwnj;in&zwnj; &zwnj;two&zwnj; &zwnj;large&zwnj; &zwnj;global&zwnj; &zwnj;Phase&zwnj; &zwnj;III&zwnj; &zwnj;studies,&zwnj; &zwnj;which&zwnj; &zwnj;looks&zwnj; &zwnj;at&zwnj;&nbsp;&zwnj;the&zwnj; &zwnj;general&zwnj; &zwnj;population&zwnj; &zwnj;of&zwnj; &zwnj;people&zwnj; &zwnj;who&zwnj; &zwnj;have&zwnj; &zwnj;Alzheimer&rsquo;s&zwnj; &zwnj;disease&zwnj; &zwnj;that&zwnj; &zwnj;has&zwnj; &zwnj;not&zwnj; &zwnj;directly&zwnj; &zwnj;been&zwnj;&nbsp;&zwnj;caused&zwnj; &zwnj;by&zwnj; &zwnj;genetic&zwnj; &zwnj;mutations.&zwnj;&nbsp;&zwnj;</p> <p>Additional&zwnj; &zwnj;analyses&zwnj; &zwnj;in&zwnj; &zwnj;understanding&zwnj; &zwnj;the&zwnj; &zwnj;totality&zwnj; &zwnj;of&zwnj; &zwnj;gantenerumab&zwnj; &zwnj;within&zwnj; &zwnj;the&zwnj; &zwnj;DIAN-TU-001&zwnj; &zwnj;study&zwnj;&nbsp;&zwnj;are&zwnj; &zwnj;being&zwnj; &zwnj;conducted&zwnj; &zwnj;by&zwnj; &zwnj;Roche&zwnj; &zwnj;with&zwnj; &zwnj;the&zwnj; &zwnj;University&zwnj; &zwnj;of&zwnj; &zwnj;Washington,&zwnj; &zwnj;and&zwnj; &zwnj;will&zwnj; &zwnj;be&zwnj; &zwnj;presented&zwnj; &zwnj;at&zwnj; &zwnj;the&zwnj;&nbsp;&zwnj;AAT-AD/PD&zwnj; &zwnj;Focus&zwnj; &zwnj;meeting&zwnj; &zwnj;in&zwnj; &zwnj;April&zwnj; &zwnj;2020.&zwnj;&nbsp;&zwnj;</p> <p>Levi&zwnj; &zwnj;Garraway,&zwnj; &zwnj;M.D.,&zwnj; &zwnj;Ph.D.,&zwnj; &zwnj;Chief&zwnj; &zwnj;Medical&zwnj; &zwnj;Officer&zwnj; &zwnj;and&zwnj; &zwnj;Head&zwnj; &zwnj;of&zwnj; &zwnj;Global&zwnj; &zwnj;Product&zwnj; &zwnj;Development&zwnj; &zwnj;of&zwnj;&nbsp;&zwnj;Roche,&zwnj; &zwnj;said&zwnj; &zwnj;in&zwnj; &zwnj;the press release:&nbsp;&nbsp;&zwnj;&zwnj;&ldquo;<em>We&zwnj; &zwnj;are&zwnj; &zwnj;very&zwnj; &zwnj;grateful&zwnj; &zwnj;to&zwnj; &zwnj;all&zwnj; &zwnj;those&zwnj; &zwnj;involved&zwnj;&nbsp;&zwnj;in&zwnj; &zwnj;this&zwnj; &zwnj;study&zwnj; &zwnj;and&zwnj; &zwnj;hope&zwnj; &zwnj;the&zwnj; &zwnj;data&zwnj; &zwnj;can&zwnj; &zwnj;further&zwnj; &zwnj;contribute&zwnj; &zwnj;to&zwnj; &zwnj;the&zwnj; &zwnj;science&zwnj;&nbsp;&zwnj;and&zwnj; &zwnj;collective&zwnj; &zwnj;understanding&zwnj; &zwnj;of&zwnj; &zwnj;this&zwnj; &zwnj;complex&zwnj; &zwnj;disease</em>.&rdquo;&zwnj;&nbsp;&zwnj;&nbsp;&zwnj;</p> <p>Despite&zwnj; &zwnj;the&zwnj; &zwnj;ending&zwnj; &zwnj;of&zwnj; &zwnj;the&zwnj; &zwnj;DIAN-TU-001&zwnj; &zwnj;study,&zwnj; &zwnj;ADI&zwnj; &zwnj;remains&zwnj; &zwnj;confident&zwnj; &zwnj;in&zwnj; &zwnj;Roche&rsquo;s&zwnj; &zwnj;commitment&zwnj; &zwnj;to&zwnj;&nbsp;&zwnj;the&zwnj; &zwnj;research&zwnj; &zwnj;into&zwnj; &zwnj;treatment&zwnj; &zwnj;for&zwnj; &zwnj;Alzheimer&rsquo;s&zwnj; &zwnj;disease&zwnj; &zwnj;and&zwnj; &zwnj;other&zwnj; &zwnj;neurological&zwnj; &zwnj;conditions.&zwnj;&nbsp;&zwnj;</p> <p>Paola&zwnj; &zwnj;Barbarino,&zwnj; &zwnj;Chief&zwnj; &zwnj;Executive&zwnj; &zwnj;of&zwnj; &zwnj;ADI&zwnj; &zwnj;said:&zwnj; &zwnj;&zwnj;&ldquo;&zwnj;<em>It&zwnj; &zwnj;is&zwnj; &zwnj;of&zwnj; &zwnj;course&zwnj; &zwnj;disappointing&zwnj; &zwnj;to&zwnj; &zwnj;see&zwnj; &zwnj;such&zwnj; &zwnj;a&zwnj;&nbsp;&zwnj;promising&zwnj; &zwnj;study&zwnj; &zwnj;in&zwnj; &zwnj;such&zwnj; &zwnj;an&zwnj; &zwnj;interesting&zwnj; &zwnj;field&zwnj; &zwnj;to&zwnj; &zwnj;come&zwnj; &zwnj;to&zwnj; &zwnj;an&zwnj; &zwnj;end.&zwnj; &zwnj;My&zwnj; &zwnj;heart&zwnj; &zwnj;goes&zwnj; &zwnj;out&zwnj; &zwnj;to&zwnj; &zwnj;all&zwnj; &zwnj;those&zwnj;&nbsp;&zwnj;researchers&zwnj; &zwnj;who&zwnj; &zwnj;have&zwnj; &zwnj;worked&zwnj; &zwnj;so&zwnj; &zwnj;hard&zwnj; &zwnj;on&zwnj; &zwnj;the&zwnj; &zwnj;project.&zwnj; &zwnj;Nevertheless&zwnj; &zwnj;it&zwnj; &zwnj;is&zwnj; &zwnj;important&zwnj; &zwnj;to&zwnj; &zwnj;remember&zwnj;&nbsp;&zwnj;that&zwnj; &zwnj;Roche&zwnj; &zwnj;is&zwnj; &zwnj;working&zwnj; &zwnj;on&zwnj; &zwnj;other&zwnj; &zwnj;important&zwnj; &zwnj;breakthroughs&zwnj; &zwnj;and&zwnj; &zwnj;that&zwnj; &zwnj;their&zwnj; &zwnj;commitment&zwnj; &zwnj;to&zwnj; &zwnj;those&zwnj; &zwnj;is&zwnj;&nbsp;&zwnj;unchanged.&zwnj; &zwnj;We&zwnj; &zwnj;thank&zwnj; &zwnj;all&zwnj; &zwnj;at&zwnj; &zwnj;Roche&zwnj; &zwnj;for&zwnj; &zwnj;continuing&zwnj; &zwnj;to&zwnj; &zwnj;keep&zwnj; &zwnj;our&zwnj; &zwnj;hopes&zwnj; &zwnj;up&zwnj;.</em>&rdquo;&zwnj;&nbsp;&zwnj;<br /> <br /> To&zwnj; &zwnj;find&zwnj; &zwnj;out&zwnj; &zwnj;more,&zwnj; &zwnj;<u><strong><a href="">read&zwnj; &zwnj;Roche&rsquo;s&zwnj; &zwnj;press&zwnj; &zwnj;release</a></strong></u>.&zwnj;&nbsp;&zwnj;</p> Mon, 10 Feb 2020 14:28:28 +0000 Taylor.Paatalo 3722 at Global Perspective Newsletter for December 2019 <p><a href="/sites/default/files/pdfs/GP%20December%202019.pdf"><img alt="" src="/sites/default/files/img/GP%20December%202019%20cover.JPG" style="float: right; width: 90px; height: 128px; border-width: 1px; border-style: solid;" /></a><strong>10 December 2019</strong> &ndash; The December&nbsp;2019 edition of our Global Perspective Newsletter is now available. Read the latest&nbsp;news from ADI, our partners and member associations, including updates on the upcoming World Alzheimer&#39;s Month, World Alzheimer Report, and much more. <a href="/sites/default/files/pdfs/GP%20December%202019.pdf">[read more]&nbsp;</a></p> Thu, 12 Dec 2019 12:00:00 +0000 Taylor.Paatalo 3719 at ADI and DAI invite you to a joint webinar on dementia and rights <!--break--> <p><strong>11&nbsp;December 2019</strong>&nbsp;&ndash; ADI is&nbsp;happy&nbsp;to announce that we will be hosting a joint webinar,&nbsp;<em><strong><a href="">Dementia &amp; rights; from principles to practice</a>,&nbsp;</strong></em>with Dementia Alliance International (DAI)&nbsp;on 27&nbsp;February 2020.</p> <p>The webinar will look at addressing key issues and principles&nbsp;surrounding human rights and dementia, and how these important concepts can be translated into mobilisation and practice.<br /> <br /> The 75-minute session will consist of seven expert panellists, with the aim of providing ideas and solutions on how governments, communities and individuals can to put dementia rights principles into practice.<br /> <br /> Read more about the webinar <a href="">here</a>.</p> <p>&nbsp;</p> <p>&nbsp;</p> <div class="field field-type-filefield field-field-news-fp-image"> <div class="field-label">Front Page Image:&nbsp;</div> <div class="field-items"> <div class="field-item odd"> <img class="imagefield imagefield-field_news_fp_image" width="634" height="322" alt="" src="" /> </div> </div> </div> Wed, 11 Dec 2019 08:32:39 +0000 Annie.Bliss 3718 at China approves first drug for mild to moderate Alzheimer's in 17 years <p><strong>4 November 2019&nbsp;</strong>&ndash;&nbsp;Chinese Pharmaceutical Company Green Valley announced over the weekend that their drug Oligomannate (GV-971) has been granted conditional approval by the National Medical Products Administration (NMPA) as&nbsp;a new drug for the treatment of &ldquo;mild to moderate Alzheimer&#39;s disease and improving cognitive function&rdquo;.</p> <p>This comes after a phase 3 trial, conducted in collaboration with IQVIA and Signant Health and other partners, with&nbsp;Green Valley saying&nbsp;that Oligomannate&nbsp;&ldquo;demonstated to statistically improve cognitive function in mild-to-moderate Alzheimer&rsquo;s patients as early as week four&rdquo;.&nbsp;The trial measured the effect of the drug on 818 patients&nbsp;with mild to moderate Alzheimer&rsquo;s in 34 Tier-1 hospitals across China.</p> <p>The drug is projected to be available in China by the end of 2019 and Green&nbsp;Valley have said they plan to submit the marketing authorization applications in selected countries thereafter. Furthermore, a multi-center global phase 3 clinical trial (GREEN MEMORY) is planned to be initiated in early 2020 to support global regulatory filing of&nbsp;Oligomannate. This will have sites in the US, Europe and Asia.</p> <p>ADI welcome this news, coming just a week after recent news about <a href="">Biogen&#39;s application for market approval of aducanumab</a>. We are very keen to see how this progresses and to help people understand some of key questions that they will ask about access to the drug, availability and cost and of course the ongoing key challenge of diagnosis.</p> <p>ADI&rsquo;s Chief Executive Officer Paola Barbarino, said: <em>&ldquo;We are encouraged by this development. We will be keenly following the next stages including the global phase 3 trial and applications for approval in other countries. After such an extended period without a disease modifying treatment breakthrough, our audiences are eager to hear about the development, timeframes, availability, access and cost.&rdquo; &nbsp;</em></p> <p>As Scientific Advisor to Green Valley, Jeffrey Cummings, MD, a member of ADI&rsquo;s Medical and Scientific Panel (MSAP), said, in the Green Valley news story, that he looks forward to the global phase 3 trial to investigate its clinical effects in larger and more diverse populations.</p> <p><em>&quot;The phase 3 clinical trial of Oligomannate conducted in China showed a sustainable cognitive benefit. It was well tolerated. This is the first new therapy for Alzheimer&#39;s disease approved in many years and we applaud this innovation,&quot;&nbsp;</em>said Cummings. <em>&quot;We look forward to the global phase 3 trial of Oligomannate&nbsp;to investigate its clinical effects in larger and more diverse populations and to collect samples that will provide evidence of the agent&#39;s biological effects.&rdquo;</em></p> <p>&nbsp;</p> <p>To find out more read <a href="">Green Valley&rsquo;s statement</a> and <a href="">this article</a> by Bloomberg.</p> Mon, 04 Nov 2019 11:56:59 +0000 Annie.Bliss 3715 at Biogen and Eisai announce plans to file for market approval of Alzheimer's drug <p><strong>22 October 2019</strong> &ndash; Biogen and Eisai today announced that they will file for market approval for the drug aducanumab, an investigational treatment for early Alzheimer&rsquo;s disease, following new analysis showing reduced clinical decline in people with early Alzheimer&rsquo;s disease.</p> <p>The Phase 3 clinical studies ENGAGE and EMERGE were <a href="">discontinued in March 2019</a> following futility analysis by an independent monitoring committee that indicated the trials were unlikely to succeed.</p> <p>Following the discontinuation of EMERGE and ENGAGE, additional data from these studies became available. After reviewing this larger dataset from the Phase 3 EMERGE Study&nbsp;in close consultation with the U.S. Food and Drug Administration (FDA), Biogen found that aducanumab resulted in significant benefits to patients. These improvements related to cognition and function including memory, orientation, and language, as well as improving daily activities like conducting personal finances, performing household chores, and independently traveling out of the home.</p> <p>The discrepancy between the earlier futility analysis of the drug and the new analysis of the larger dataset is largely due to patients&rsquo; greater exposure to high dose aducanumab.</p> <p>Alzheimer&rsquo;s disease is the most common form of dementia, the collective term for a range of degenerative neurological conditions that affect memory, thinking, behaviour and emotion. There is no cure for dementia and has been no new treatment for the symptoms of dementia since 2002.</p> <p>If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer&rsquo;s disease and would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes.</p> <p>Paola Barbarino, Chief Executive Officer of ADI, said: <em>&ldquo;This amazing therapeutic breakthrough from Biogen is like a ray of sunshine, the first we have had for a long, long time. I cannot overemphasise the importance of this announcement today as it will give also renewed impetus to markets for the discovery of more pharmaceutical treatments. I want to stress to all those living with dementia now that aducanumab is&nbsp;not yet approved and further submissions will be made to regulators</em> <em> but it is the light at the end of the tunnel we have been hoping for so long!</em>&rdquo;</p> <p>Samantha Budd Haeberlein, Vice President, Late-Stage Clinical Development at Biogen, said: <em>&ldquo;We believe that these positive results for aducanumab represent a turning point for patients, caregivers, physicians, and scientists in the fight against Alzheimer&rsquo;s disease. We look forward to working with the FDA and regulators around the world to find a path to make the drug available to patients. Most importantly, we envisage a future where physicians may finally have an option to offer patients to help reduce clinical decline in Alzheimer&rsquo;s disease.&rdquo;</em></p> <p>Kate Swaffer, Chair, CEO and Co-Founder of Dementia Alliance International (DAI), said: <em>&ldquo;It is with both excitement, but also some apprehension that people diagnosed with dementia receive this news. For too long the focus was only on a cure, and we have also had many failed trials. To know we may be close to a disease modifying drug, as we have for so many other chronic conditions such as diabetes, increases hope for us all.&rdquo;</em></p> <p>We are assured that Biogen will work to gain market approval for aducanumab as soon as possible, working closely with regulatory authorities, institutional review boards and principal investigators. They plan to submit their Biologics License Application to the FDA by early 2020 and will continue dialogue with regulatory authorities in international markets.</p> <p>The clinical trial for this drug is not open to new patients at present, but Biogen aims to offer aducanumab to eligible patients previously enrolled in clinical studies. ADI will continue to work closely with Biogen and Eisai, and to advocate for improvements in detection and diagnosis, availability of specialists and access to healthcare centers, to support the eventual roll-out of aducanumab.</p> <p>More information on this ground-breaking new drug will be available at the 34th International Conference of ADI in Singapore in March 2020.</p> <p>To answer any questions you might have, Biogen have created a website with information for patients and caregivers, previously enrolled trial participants, principal investigators and key medical experts in the U.S. at <a href=""></a>.</p> <p>To find out more, read <a href="">Biogen&rsquo;s press release</a>.</p> Tue, 22 Oct 2019 12:03:49 +0000 Annie.Bliss 3713 at Dementia given high priority at G20 Health Ministers Meeting <!--break--> <p><strong>21 October 2019&nbsp;</strong>&ndash;&nbsp;2019 has been a significant year of advocacy by Alzheimer&rsquo;s Disease International (ADI), during the Japanese Presidency of the G20. Over the weekend, ADI&rsquo;s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer&#39;s Association Japan (AAJ) were in Japan in the build-up to the G20 Health Ministers Meeting, to focus attention and to keep the momentum going from their work earlier this year during the <a href="">Osaka Summit</a>.</p> <p>The Health Ministers Meeting, which brought together Ministers of Health from 19 countries and the European Union, as well as invited guest countries and organisations, facilitated high-level discussion of major issues of global health. ADI, in coordination with its members in G20 countries, sent letters of support to each Minister of Health, calling for strong leadership to ensure that the commitments made in the G20 Osaka summit declaration about dementia were delivered. Dementia indeed featured heavily in the <a href="/sites/default/files/pdfs/G20%20Okayama%20Declaration%202019.pdf">Okayama Declaration of the G20 Health Ministers</a>, displaying an ongoing commitment of the G20 to addressing the biggest health and social care crisis of the 21st century.</p> <p>The Okayama Declaration contained various important commitments around dementia, spanning six articles of the document.<br /> <br /> Article 29 states: <em>&ldquo;We commit to developing and implementing multi-sectoral national action plans, adopting integrated approaches on dementia in line with the Global Action Plan to improve the quality of care and the quality of life of people with dementia, their families and caregivers.&rdquo;</em></p> <p>Currently there are only 32 national plans in existence against a WHO target of 146 by 2025.&nbsp; National plans are the most important tools for governments in developing a strategy to tackle dementia and we are reassured by G20 countries taking such a global lead.</p> <p>Article 30 of the Declaration addressed risk factors and social determinants of dementia, early detection, diagnosis, and interventions and strengthening primary health care.</p> <p>An important commitment was: &ldquo;<em>We also recognize the importance of including older persons with disabilities in efforts to support healthy and active ageing, including the provision of social and health services in line with the UN Convention on the Rights of Persons with Disabilities.&rdquo;</em></p> <p>ADI and AAJ welcome the strong commitments to Healthy Ageing, with specific commitment to&nbsp;achieving the 2030 Agenda for Sustainable Development and&nbsp;the Decade of Ageing.&nbsp;</p> <p>Paola&rsquo;s visit to Japan was in recognition that Japan has been a leader in dementia and healthy ageing for a number of years and to ensure that they continue to take this role as global leader further. Paola began the trip in Tokyo by speaking at the <a href="">World Dementia Council</a> meeting, highlighting the global impact of dementia and the need for governments&rsquo; to honour their commitment made at the <a href="">World Health Assembly in 2017</a> by developing, implementing and fully funding national dementia plans. She spoke with Asahi Shinbun newspaper, highlighting key aspects of dementia policy, including stigma, prevention and dementia friendly initiatives during a two-hour interview. She then met with a cross-party group of Japanese Parliamentarians for in-depth discussion of Japan being a global leader in dementia response and a forthcoming updated Japanese dementia strategy.</p> <p>Paola said<em>: &ldquo;This is a watershed moment for ADI and the international dementia movement. Everything we asked for in the last year is present in this Declaration, from policy making to awareness, risk reduction, care, support for carers, data and research and it includes a strong reference to the Convention on the Rights of Persons with Disabilities (CRPD). We also note the strong acknowledgement of the WHO Global Action plan (which we worked so hard for) and the reference to the role that OECD can play. The overall framing into the importance of encouraging healthy ageing is also extremely relevant. </em></p> <p><em>&ldquo;We know that lots of wonderful words do not make this a reality and we will continue to monitor the execution of these intentions very closely,&nbsp;but we are heartened and encouraged and feel the G20&nbsp;Health&nbsp;Ministers have really listened to our plea&nbsp;to create a better life for people living with dementia and their&nbsp;carers.&rdquo;</em></p> <p>Noriyo Washizu (AAJ) was also very encouraged by the Declaration, saying: <em>&ldquo;One of the most significant things is that &quot;People with&nbsp;dementia, the families and the caregivers&quot;&nbsp;appeared a key focus. AAJ will continue to support the Government to focus on building an inclusive society, and we will be active partners in the development of the new dementia strategy, which will improve the lives of the 7 million people who are projected to live with dementia in Japan by 2025.&rdquo;</em></p> <p>ADI and its members are delighted to see the ongoing commitment of the G20 in a number of key areas of the Health Ministers Meeting declaration. Japan has been a leader in dementia and healthy ageing for a number of years and it is most encouraging to see that the Government has been so willing to engage with civil society throughout this process. This level of open dialogue will ensure that dementia received the attention and robust policy action it so urgently needs.</p> <ul> <li><a href="/sites/default/files/pdfs/G20%20Okayama%20Declaration%202019.pdf">Read the Okayama Declaration</a></li> </ul> Mon, 21 Oct 2019 10:29:36 +0000 Annie.Bliss 3712 at ADI interviewed by major Japanese newspaper ahead of G20 meeting <!--break--> <p><strong>20 October 2019&nbsp;</strong>&ndash;&nbsp;During a trip to Japan in October last year, Paola Barbarino was interviewed by Asahi Shimbun newspaper in Tokyo. The purpose of the trip was to engage with Ministers, Parliamentarians and the media around the G20 Health Ministers Meeting, which took place in Okayama, which resulted in <a href="">major commitments to dementia</a>.</p> <p>Asahi Shimbun &ndash; one of Japan&rsquo;s largest national newspapers &ndash; has been active in helping to promote dementia friendly movements in the country. ADI would like to thank Noriyo Washizu of Alzheimer&rsquo;s Association Japan (AAJ) for coordinating and also Takuji Kiyokawa, staff writer and Kayo Tomono, Chief Editor of Asahi, for shedding light on this important topic.</p> <p>This is an excellent example of how ADI can work with its members to draw national media attention to important topics such as this. Please contact <a href=""></a> for any opportunities.</p> <p><img alt="" src="/sites/default/files/img/Paola%20and%20the%20G20-min.jpg" style="width: 640px; height: 427px; margin-left: 25px; margin-right: 25px;" /></p> <p align="center"><strong>Pictured: Paola Barbarino (ADI) and Noriyo Washizu (Alzheimer&rsquo;s Association Japan) with members of The National Diet of Japan</strong></p> <p style="margin-left:5.5pt;"><strong>70,000 responded to the global survey on Attitudes to Dementia </strong></p> <ul> <li align="left">ADI conducted a global online survey targeting people living with dementia, their carers, and healthcare professionals involved in the dementia field and the public,</li> <li align="left">The result shows that lingering discrimination and negative attitudes to dementia still exist in the world.</li> <li align="left">Asahi newspaper interviewed Paola Barbarino, CEO of Alzheimer&rsquo;s Disease International, about future strategies, including in the area of dementia risk reduction.</li> </ul> <hr /> <ul> <li>The number of people living with dementia is more than 50 million at present and it is estimated to increase threefold, to 152 million by 2050.</li> <li align="left">ADI conducted a global online survey from April to June 2019 and collected almost 70,000 responses from 155 countries and published the results on 21 September 2019, World Alzheimer&rsquo;s Day.</li> <li align="left">The results were analysed according to four categories; people living with dementia, family carers, medical professionals, and the general public.</li> <li align="left">According to the report, over 85% of people living with dementia answered that people do not take their opinions or ideas seriously.</li> <li align="left">52% of family carers reported having health problems and 49% have problems with work due to caring of their family members who have dementia.</li> <li align="left">20.2% of the general public said they would hide their dementia when meeting people. (The number is 19.7% in Japan)</li> <li align="left">Regarding the perception of dementia, 63.6% of the general public think people living with dementia are impulsive and unpredictable and the number in Japan is 46.8%.</li> </ul> <hr /> <p align="center"><strong>Dementia, Forward the society with no need for guilty feeling</strong></p> <p align="center">Interview with Paola Barbarino</p> <p align="center">interviewed by Kayo Tomono, Chief writer<img alt="" src="/sites/default/files/img/Japan%20news%20item.png" style="width: 500px; height: 224px; float: left; margin-left: 80px; margin-right: 80px;" /></p> <p align="center"><strong>&nbsp;</strong></p> <p align="center">&nbsp;</p> <p align="center">&nbsp;</p> <p align="center">&nbsp;</p> <p align="center">&nbsp;</p> <p align="center">&nbsp;</p> <p align="center">&nbsp;</p> <p align="center"><strong>35</strong><strong>%</strong><strong> of family carers hide the diagnosis of a person with dementia</strong></p> <p><strong>T: What do you think about the result of the survey?</strong></p> <p style="margin-left:16.55pt;"><strong>P</strong>: 35 % of family carers have hidden their family members&rsquo; dementia. It is conceivable that they were afraid of discrimination and isolation after coming out. The wife of the person with dementia in Mexico &ndash; one of the case studies in the report - considered committing double suicide. One of the people living with dementia answered that his wife divorced him because of his dementia. Another answered that &ldquo;my doctor started to talk to my family carer instead of me when he found I had dementia&rdquo;. These are shocking stories.</p> <p><strong>T: How to bring the result into play?</strong></p> <p><strong>P</strong>: We use these&nbsp;results to abolish the discrimination and to change attitudes to dementia, calling for governments to collaborate with civil society organizations across the world, such as Alzheimer&rsquo;s Association Japan. Also, care for people living with dementia is a very important and urgent issue. Governments tend to emphasize prevention more than care, taking a forward-thinking perspective. But they should put more effort into developing the quality of care now.</p> <p><strong>T: what do you think about the situation in Japan?</strong></p> <p><strong>P</strong>: I commend the Japanese approach. The broad outline of dementia policy announced in June 2019 includes harmonious coexistence. The idea of social inclusion is very significant. Japan is aware of this issue and is taking action.</p> <p align="center" style="margin-left:16.5pt;"><strong>Risk reduction is possible but perfect prevention is not.</strong></p> <p><strong>T: Another main agenda is prevention. What do you think about prevention?</strong></p> <p><strong>P</strong>: Prevention is by no means the wrong word. But there are complicated matters regarding the word &ldquo;prevention&rdquo;. There is no conclusive scientific evidence to prevent dementia completely. Statistic studies show that no smoking, exercise and reduced alcohol consumption may reduce the risk of developing dementia. However, there is no evidence that this definitely prevents you from developing dementia. Therefore, &ldquo;risk reduction&rdquo; is a more appropriate expression instead of &ldquo;prevention&rdquo;.</p> <p><strong>T: There is also an apprehension that the emphasis of prevention can have a negative impact on people living with dementia and that they might feel difficulty in their lives. </strong></p> <p><strong>P</strong>: People living with dementia should not feel guilty because there is no prevention for dementia. If the word prevention causes them difficulty, changing the word is one strategy. There might be an appropriate expression in each language. Japan had such experience, when they changed the word for dementia from &ldquo;Chihosho&rdquo; which means idiot and senile to &ldquo;Ninchisho&rdquo; which means cognitive impairment syndrome.</p> Sat, 19 Oct 2019 23:00:01 +0000 Annie.Bliss 3720 at